A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment.

Denna fas II-pilot var en 12 veckor lång dubbelblind randomiserad placebokontrollerad studie av nikotinamidribosid hos vuxna med amnestisk lätt kognitiv svikt. Fyrtiotvå deltagare fullföljde behandlingen: 22 fick nikotinamidribosid och 20 placebo. The study assessed safety, tolerability, cognitive function, cerebral blood flow and blood pressure.

Adherence was similar between groups, and the abstract reports no serious adverse effects. Nicotinamide riboside doubled blood NAD in the active-treatment group. That biochemical change did not translate into improvement in the primär cognitive outcome. It also did not improve total cerebral blood flow or blood pressure, which were secondary outcomes. Exploratory analyses suggested possible increases in regional cerebral blood flow, particularly in the hippocampus, but this was not a confirmed primär or secondary result.

The study is relevant to a specific clinical population with cognitive impairment rather than healthy ageing. Its clearest result is that the supplement raised NAD over 12 weeks. It provides no evidence of cognitive benefit during that period. Any regional blood-flow signal remains exploratory and needs confirmation in a larger, longer trial.

Nicotinamide riboside raises NAD in people with mild cognitive impairment but did not improve cognition, total cerebral blood flow or blood pressure over 12 weeks.